Trials / Completed
CompletedNCT01152645
Study of ARQ 197 Monotherapy
Phase II Study of ARQ 197 Monotherapy for Previously Treated Advanced/Recurrent Gastric Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
A phase II open-label study with ARQ 197 administered orally and twice daily as monotherapy in patients with previously treated advanced/recurrent gastric cancer. The primary endpoint is disease control and the secondary efficacy endpoints include antitumor effect (tumor response), progression-free survival and overall survival. The pharmacokinetic profile and the safety profile are also evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ 197 | Orally twice daily administration of ARQ 197 |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2010-06-29
- Last updated
- 2017-03-15
Locations
2 sites across 2 countries: Japan, South Korea
Source: ClinicalTrials.gov record NCT01152645. Inclusion in this directory is not an endorsement.